5651-60-5

Usage

Uses

Used in Material Science:
Benzdindeno1,2-bpyran-5,11-dione is utilized as a key component in the development of advanced materials. Its unique structural and electronic properties contribute to the creation of materials with enhanced performance characteristics.
Used in Organic Synthesis:
In the field of organic synthesis, Benzdindeno1,2-bpyran-5,11-dione serves as a valuable intermediate or reactant in various chemical reactions and processes. Its distinctive properties make it suitable for the synthesis of complex organic compounds.
Used in Pharmaceutical Industry:
Benzdindeno1,2-bpyran-5,11-dione is employed as a potential candidate in drug development. Its unique chemical and physical properties make it a promising molecule for the creation of new pharmaceuticals with novel therapeutic effects.

InChI:InChI=1/C16H8O3/c17-14-10-6-2-3-7-11(10)15-13(14)9-5-1-4-8-12(9)16(18)19-15/h1-8H

Upstream product

• 87-41-2 2-benzofuran-1(3H)-one 
• 16859-59-9 3-hydroxy-1(3H)-isobenzofuranone 
• 89-51-0 Homophthalic acid 
• 119-67-5 o-carboxybenzaldehyde 
• 19147-02-5 2-(2-carboxyphenyl)indan-1,3-dione 
• 15255-42-2 11-acetoxy-6-bromo-6H-dibenzo[a,e]cycloocten-5-one 

Downstream Products

• 5264-21-1 5,6-dihydro-5,11-diketo-11H-indeno[1,2-c]isoquinoline 
• 148317-76-4 6-[2-(2-hydroxyethyl)aminoethyl]-5,11-dioxo-5,6-dihydro-11H-indeno[1,2-c]isoquinoline 
• 281223-41-4 6-(4-methoxybenzyl)-5H-indeno[1,2-c]isoquinoline-5,11(6H)-dione 
• 81721-78-0 6-propargyl-5H-indeno[1,2-c]isoquinoline-5,11(6H)-dione 
• 81721-81-5 6-(Furan-2-ylmethyl)-5H-indeno[1,2-c]isoquinoline-5,11(6H)-dione 
• 81721-76-8 6-butyl-5H-indeno[1,2-c]isoquinoline-5,11(6H)-dione 
• 1374209-85-4 N-(3-(5,11-dioxo-5H-indeno[1,2-c]isoquinolin-6(11H)-yl)propyl)-4-methylbenzenesulfonamide 
• 1374209-78-5 N-(7-(5,11-dioxo-5H-indeno[1,2-c]isoquinolin-6(11H)-yl)heptyl)benzenesulfonamide 
• 1374209-77-4 N-(6-(5,11-dioxo-5H-indeno[1,2-c]isoquinolin-6(11H)-yl)hexyl)benzenesulfonamide 
• 1374209-76-3 N-(5-(5,11-dioxo-5H-indeno[1,2-c]isoquinolin-6(11H)-yl)pentyl)benzenesulfonamide 
• 1374209-75-2 N-(4-(5,11-dioxo-5H-indeno[1,2-c]isoquinolin-6(11H)-yl)butyl)benzenesulfonamide 
• 1374209-74-1 N-(3-(5,11-dioxo-5H-indeno[1,2-c]isoquinolin-6(11H)-yl)propyl)benzenesulfonamide 
• 1374209-73-0 N-(2-(5,11-dioxo-5H-indeno[1,2-c]isoquinolin-6(11H)-yl)ethyl)benzenesulfonamide 
• 1352142-56-3 6-(5,11-dioxo-5H-indeno[1,2-c]isoquinolin-6(11H)-yl)hexyl-4-methylbenzenesulfonate 

Relevant academic research and scientific papers

Iridium(iii) complexes as mitochondrial topoisomerase inhibitors against cisplatin-resistant cancer cells

Herein, we developed the first metal-based mitochondrial topoisomerase inhibitors to achieve an effective therapeutic outcome for the therapy of cisplatin-resistant tumour cells. This journal is

Indene isoquinoline derivative labeled with stable nitrogen-oxygen free radicals, and preparation method and application

The invention discloses an indene isoquinoline derivative labeled with stable nitrogen-oxygen free radicals, and a preparation method and application thereof in preparation of anti-tumor medicines. The indene isoquinoline derivative has the advantages that the good inhibiting activity is realized on the tumor cell lines, and one part of activity of the compound is equivalent to the activity of theexisting clinical topotecan medicine; the indene isoquinoline derivative can be used for preparing the anti-tumor medicines.

Synthesis and cytotoxic evaluation of novel indenoisoquinoline-propan-2-ol hybrids

The synthesis of N-substituted indenoisoquinolines was performed by applying a two-step condensation between 2-carboxybenzaldehyde and phthalide, followed by treatment with various primary amines. N-allylindenoisoquinoline was subsequently selected as a s

SYNTHESIS AND USE OF DUAL TYROSYL-DNA PHOSPHODIESTERASE I (TDP1)- TOPOISOMERASE I (TOP1) INHIBITORS

The invention described herein pertains to the synthesis and use of certain N-substituted indenoisoquinoline compounds which inhibit the activity Tyrosyl-DNA Phosphodiesterase I (Tdp1) or Topoisomerase I (Top1) or both, or otherwise demonstrate anticancer activity. Also disclosed are novel N-substituted indenoisoquinoline compounds and pharmaceutical compositions comprising the novel N-substituted indenoisoquinoline compounds.

Synthesis and biological evaluation of the first dual tyrosyl-DNA phosphodiesterase i (Tdp1)-topoisomerase i (Top1) inhibitors

Substances with dual tyrosyl-DNA phosphodiesterase I-topoisomerase I inhibitory activity in one low molecular weight compound would constitute a unique class of anticancer agents that could potentially have significant advantages over drugs that work against the individual enzymes. The present study demonstrates the successful synthesis and evaluation of the first dual Top1-Tdp1 inhibitors, which are based on the indenoisoquinoline chemotype. One bis(indenoisoquinoline) had significant activity against human Tdp1 (IC 50 = 1.52 ± 0.05 μM), and it was also equipotent to camptothecin as a Top1 inhibitor. Significant insights into enzyme-drug interactions were gained via structure-activity relationship studies of the series. The present results also document the failure of the previously reported sulfonyl ester pharmacophore to confer Tdp1 inhibition in this indenoisoquinoline class of inhibitors even though it was demonstrated to work well for the steroid NSC 88915 (7). The current study will facilitate future efforts to optimize dual Top1-Tdp1 inhibitors.

A short and efficient construction of the dibenzo[c,h]chromen-6-one skeleton

We hereby report a major revision of the synthetic methodology for construction of the dibenzochromenone skeleton. Homophthalic acid derivatives were reacted with thionylchloride/DMF in the presence of NaN 3. As the main product, dibenzochromen

Indeno[1,2-c]isoquinolin-5,11-diones conjugated to amino acids: Synthesis, cytotoxicity, DNA interaction, and topoisomerase II inhibition properties

Three series of indeno[1,2-c]isoquinolin-5,11-dione-amino acid conjugates were designed and synthesized. Amino acids were connected to the tetracycle through linkers with lengths of n = 2 and 3 atoms using ester (series I), amide (series II), and secondary amine (series III) functions. DNA binding was evaluated by thermal denaturation and fluorescence measurements. Lysine and arginine substituted derivatives with n = 3 provided the highest DNA binding. Arginine derivative 32 (n = 2, series II) and glycine derivative 34 (n = 2, series III) displayed high topoisomerase II inhibition. Incrementing the length of the N-6 side chain from two to three methylene units provided a significant increase in DNA affinity but a substantial loss in topoisomerase II inhibition. The most cytotoxic compounds toward HL60 leukemia cells were 19, 33, and 34 displaying micromolar IC50 values. When tested with the topoisomerase II-mutated HL60/MX2 cell line, little variation of IC50 values was found, suggesting that topoisomerase II might not be the main target of these compounds and that additional targets could be involved.

N-SUBSTITUTED INDENOISOQUINOLINES AND SYNTHESES THEREOF

N-Substituted indenoisoquinoline compounds, and pharmaceutical formulations of N-substituted indenoisoquinoline compounds are described. Also described are processes for preparing N-substituted indenoisoquinoline compounds. Also described are methods for

Synthesis of benz[d]indeno[1,2-b]pyran-5,11-diones: Versatile intermediates for the design and synthesis of topoisomerase I inhibitors

A method has been developed that relies on a two-step, one-pot condensation between phthalide and 2-carboxybenzaldehydes to provide benz[d]indeno[1,2-b] pyran-5,11-diones in a multi-gram fashion. Treatment of these compounds with a primary amine allows ra

TOPOISOMERASE INHIBITORS AND PRODRUGS

Compositions and methods for treating cancer and other hyperproliferatice disease conditions with topoisomerase inhibitors and their prodrugs are disclosed.